Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
SIGA SIGA Technologies
8.080
+0.060+0.75%
Post Mkt Price
8.070
-0.010-0.12%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- -- -44.78% 202.8704 -12.98% 207.2056 92.05% 369.5103
Receivable Turnover(T)
-- -- 152.44% 10.999 -33.25% 29.8487 -90.77% 3.0732
Inventory Turnover(T)
-- -- 64.78% 2.0382 29.10% 1.7585 -22.42% 1.3347
Fixed Assets Turnover(T)
-- -- 62.84% 62.6341 16.43% 65.9813 13.01% 59.8085
Total Asset Rate(T)
-- -- 33.64% 1.0041 -12.74% 0.8623 2.23% 0.7333
ROIC
-- -- 35.05% 55.759% -21.17% 47.993% 19.76% 45.538%
ROE
-- -- 34.99% 55.963% -21.24% 48.138% -7.75% 45.675%
ROA
-- -- 42.11% 48.885% -13.64% 43.241% 17.80% 38.101%
FCF to Sales
-- -- -34.17% 48.982% 5.03% 52.348% -85.04% 8.561%
FCF to Net Income
-- -- -38.09% 100.605% 6.12% 104.390% -87.02% 16.478%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -- 27.18% 57.094%
Profitability Ratios TTM
Gross Margin
-- -- -4.01% 75.090% -4.30% 76.859% 0.93% 80.142%
Operating Margin
-- -- 4.03% 62.895% -5.48% 64.308% -1.44% 66.651%
Net Margin
-- -- 6.34% 48.687% -1.03% 50.146% 15.23% 51.957%
EBITDA Margin
-- -- 4.60% 0.6339% -2.54% 0.6484% 8.99% 0.6721%
R & D Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Total Assets to Common Equity
-- -- -0.09% 114.432% -2.73% 110.022% 6.71% 123.184%
Debt to Asset Ratio
-- -- -2.29% 0.363% -9.62% 0.290% -22.76% 0.268%
Current Ratio
-- -- -42.27% 9.2035 38.26% 24.4608 -50.02% 6.8471
Quick Ratio
-- -- -39.41% 8.0345 48.86% 21.9043 -47.02% 6.1267
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -129.60% -34.563%
Revenue CAGR(5Y)
-- -- -- -- -- -- -24.30% 54.903%
Net Income CAGR(3Y)
-- -- -- -- -- -- -- -45.191%
FCF 1 Year Growth
-- -- -- -- -- -- -- -83.995%
FCF CAGR(3Y)
-- -- -- -- -- -- -- -44.996%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.
CEO: Mr. Phillip Louis Gomez
Market: NASDAQ
Listing Date: 09/09/1997
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist